Clinical trial Recruiting at 1 site Interventional Ages 18 Months to 80

Effects of High-Frequency Oscillatory Ventilation in ICU Patients

Official title: Physiological Effects and Safety of Continuous High-frequency Oscillatory Ventilation in ICU Patients

Run by Shanghai Zhongshan Hospital · NCT06702813 · Data updated 2026-11-12

This study is testing whether a new breathing treatment called Continuous High-Frequency Oscillatory Ventilation can improve lung function and comfort for awake ICU patients with collapsed lungs.

Quick facts

Study typeInterventional
Ages18 Months to 80 Years
SexAll
Enrollment45 (estimated)
SponsorShanghai Zhongshan Hospital
Academic / other
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedNovember 19, 2024
Main results expectedDecember 1, 2025
Study endsDecember 1, 2025
Registry record updatedNovember 25, 2024
Trial IDNCT06702813 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are ICU patients aged 18 to 90 with atelectasis who are alert and able to communicate.

Probably not a fit

Patients with severe chronic respiratory diseases or significant hemodynamic instability may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study evaluates the safety and efficacy of Continuous High-Frequency Oscillatory Ventilation (CHFO) in awake ICU patients suffering from atelectasis. The study aims to assess pulmonary function by comparing chest electrical impedance tomography (EIT) measurements before and after CHFO treatment. A minimum of 45 patients will be enrolled, and their vital signs and subjective comfort ratings will be collected throughout the treatment process. The goal is to determine the impact of CHFO on lung function and patient comfort in a critical care setting.

Why it matters

Potential benefit: If successful, this study could improve lung function and comfort for critically ill patients with atelectasis.

How similar studies have gone: While the use of CHFO has been explored, this specific evaluation in awake critically ill patients is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients older than 18 and younger than 90 years;
* Admitted to the ICU after December 1, 2024, who are alert, with a GCS of 15, normal comprehension, and able to communicate clearly through speech or writing.
* Patients with atelectasis, who are receiving oxygen therapy, high-flow oxygen, or are on a ventilator via tracheostomy.
* Signed informed consent for MetaNeb treatment.

Exclusion Criteria:

* Refusal to participate in the proposed study.
* Age \< 10 years;
* Pregnancy;
* Significant hemodynamic instability defined as an increase of more than 20% in catecholamine doses in the last hour, despite optimization of blood volume, for a target mean blood pressure between 65 and 75 mmHg.
* Participation in another trial within 30 days prior to meeting eligibility criteria;
* Severe chronic respiratory disease requiring long-term oxygen therapy or home mechanical ventilation;
* Pneumothorax. With a clear tracheoesophageal fistula

Where it's running

  • Zhongshan Hospital, Fudan University
    Shanghai, Shanghai Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.